Is 99mTechnetium Pertechnetate Thyroid Uptake accurate in Thyrotoxicosis Evaluation?

doi:10.21203/rs.3.rs-34343/v1

Download PDF

Research article

Is 99mTechnetium Pertechnetate Thyroid Uptake accurate in Thyrotoxicosis Evaluation?

https://doi.org/10.21203/rs.3.rs-34343/v1

This work is licensed under a CC BY 4.0 License

Version 1

posted

You are reading this latest preprint version

Background

This study aimed to evaluate the 99mTc thyroid uptake (TcTU) in terms of (1) normal mean and range, (2) level of uncertainty in thyrotoxic patients and (3) effectiveness of adding radioiodine uptake in patients with uncertain TcTU values.

Methods

Patients referred for TcTU test were included and categorized into groups: euthyroid, Graves’ disease, toxic nodular goiter and subacute thyroiditis. Mean and range of TcTU were obtained separately for each group. Second radioiodine uptake test was performed in patients who had uncertain TcTU (overlap with normal range).

Results

209 patients were included (54 euthyroid, 112 Graves’ disease, 29 toxic nodules and 17 subacute thyroiditis patients). Normal mean and range of TcTU were 1.5 +/- 1.1% and 0.17-4.8%, respectively. Mean TcTU was high in hyperthyroid patients and was extremely low in subacute thyroiditis patients, however, uncertain values was noted in about 30% of the patients. TcTU was uncertain in 39 hyperthyroid patients and in 10 subacute thyroiditis patients, while second radioiodine uptake was high in the former and extremely low in the latter.

Test sensitivity was 68%, specificity was 100%, positive predictive value (PPV) was 100%, negative predictive value (NPV) was 52% and accuracy was 76%.

Conclusion

TcTU major disadvantage is the uncertainty seen in third of patients degrading test sensitivity and accuracy. We managed to overcome this uncertainty by adding second radioiodine thyroid uptake test. Accordingly, single visit TcTU was accurate and sufficient in about two thirds of patients while the remainder required second radioiodine uptake to reach accurate diagnosis.

Endocrinology & Metabolism

Thyroid

Uptake

99mTc

radioiodine

thyrotoxicosis

Thyrotoxicosis is a common endocrine medical problem manifested clinically by several non-specific symptoms (including but not limited to tremor, palpitation, excessive sweating, weight loss, diarrhea, nervousness... etc.) and confirmed biochemically by thyroid function text (TFT). Biochemically, thyrotoxic patient has suppressed thyroid stimulating hormone (TSH) with elevated thyroid hormones (T3 and T4). Thyroid scan and uptake is the test of choice for thyroid function evaluation that could discriminate between causes of thyrotoxicosis. Causes of thyrotoxicosis include subacute thyroiditis, Graves’ disease and toxic nodular goiter (1, 2). Technetium-99m (99mTc) pertechnetate is becoming radiotracer of choice in thyroid uptake evaluation owing to its low cost, ready availability, rapid single visit imaging, lower radiation burden to the patient and good image quality (1). Iodine-123 (123I) is expensive and requires a return visit by the patient next day (1). Iodine-131 (131I) has high radiation burden on the patients so it is abandoned in developed countries (2).

However, reported major disadvantages of 99mTc thyroid uptake are narrow normal uptake range of 0.5-4% and overlap between normal range and ranges of thyrotoxic patients (3, 4). Accordingly, some endocrinologists and some nuclear physicians agree on conducting 99mTc thyroid uptake but with some level of uncertainty about the results.

This study aimed to evaluate the 99mTc thyroid uptake in terms of (1) normal mean and range in our euthyroid patients, (2) level of uncertainty in thyrotoxic patients and (3) effectiveness of adding radioiodine uptake in patients with uncertain 99mTc uptake values.

Patients included in this study were those referred to our nuclear medicine department for thyroid scan and uptake. The study started in March 2016 and ended in April 2018. The study was approved by Jordan University of Science and Technology institutional review board (IRB). Consents were waived according to hospital policy. Patients were referred for investigation of thyrotoxicosis confirmed biochemically by TFT test. However, some euthyroid patients (normal TFT) were also referred and included in the study. Main reasons for euthyroid patient referral were thyroid nodule evaluation and thyrotoxic symptoms as well as borderline TFT (low normal TSH). All patients underwent 99mTc thyroid scan and uptake. Normal 99mTc uptake reference range in our department is 0.4-4% according to data published by Atkin (3). Second thyroid uptake test utilizing radioiodine was performed in thyrotoxic patients who had uncertain 99mTc uptake that was within the normal reference range. Our local mean reference range of radioiodine 131I thyroid uptake is 15% +/- 7% according to our previously published data (2). Based on image findings and uptake value, patients were categorized into the following groups: normal, Graves’ disease, toxic nodular goiter (single or multiple) and subacute thyroiditis. Mean and range of 99mTc thyroid uptake were obtained separately in the following groups: euthyroid patients, Graves’ disease patients, Toxic nodular patients and subacute thyroiditis patients. As far as patients who underwent second thyroid uptake test utilizing radioiodine 131I; mean and range of radioiodine 131I thyroid uptake were also obtained for same groups.

Clinically, all thyrotoxic patients included in this study were followed up by endocrinology clinics and treated according to diagnosis. We looked up the type of treatment and range of follow up for each group to validate the diagnosis obtained by thyroid scan and uptake.

Statistics:

Sensitivity, specificity, positive predicative valve (PPV) and negative predicative value (NPV) for 99mTc thyroid uptake in thyrotoxicosis were calculated. Moreover; accuracy of 99mTc thyroid uptake in thyrotoxicosis was calculated.

Technique:

99mTc Scintiscan:

30 minutes after intravenous administration of 18.5-MBq (5 mCi) 99mTc pertechnetate, 5 minutes static thyroid images were obtained in anterior, right anterior oblique and left anterior oblique views while the patient is supine with extended neck. Images were obtained by a large-field-of-view gamma camera (Mediso, Anyscan, Budapest, Hungary) fitted with low energy all-purpose parallel hole collimator. Image data were recorded on a 128 × 128 computer matrix.

99mTc Thyroid uptake measurement:

99mTc thyroid uptake was obtained utilizing MEDISO thyroid uptake software. Data required by the software are: injected dose measured by MBq in the syringe and time of measurement, syringe residual dose measured by MBq and time of measurement, thyroid region of interest (ROI) and neck background ROI.

Measurement of 24-hour radioiodine Thyroid uptake:

24 hours after oral administration of an average of 1.85 MBq (50 microCi) I131 capsule, uptake was measured with a thyroid probe (Biodex medical systems, Atomlab 950, CA, USA). Patients were seated facing the detector which was positioned 25 cm from the anterior surface of the patient's neck at the level of the cricoid. Patient's thigh count is obtained for 1 minute. The administered capsule is placed 25 cm from the detector and counted for one minute just before administration. Phantom was used. The radioiodine uptake (RIU) is calculated using the following relationship:

RIU = neck counts (cpm) - thigh counts (cpm)/administered counts (cpm) - background counts (cpm) x 100%.

Patient group characteristics are summarized in Table 1. Two-hundred and nine patients were included in our study. About 72% of the patients were females and 28% were males. Most patients were middle aged with average (± SD) of 43 (± 15) y and range of 7–81 y. Thyrotoxic patients had suppressed TSH and elevated T3 and T4 hormones as shown in Table 2. All patients underwent 99mTc thyroid scan and uptake, whereas only 60 patients had combined 99mTc /radioiodine thyroid uptake because of uncertain 99mTc uptake values.

Table 1

showing number, age and gender of patients who underwent 99mTc thyroid scan and uptake. Patients are classified as normal (euthyroid), hyperthyroid (Graves’ disease or toxic nodules) or subacute thyroiditis.
	Normal (Euthyroid)		Graves’ Disease		Toxic Nodules		Subacute Thyroiditis		Total
	No F:M	Age (Y) Range (mean +/- SD)	No. F:M	Age (Y) Range (mean +/- SD)	No. F:M	Age (Y) Range (mean +/- SD)	No. F:M	Age (Y) Range (mean +/- SD)
99mTc	54 38:16	7–78 (44 +/-16)	112 79:33	15–72 (40 +/- 13)	26 20:6	20–81 (46 +/-15)	17 14:3	22–73 (39 +/- 15)	209

Table 2

showing thyroid function test results in patient groups. Local laboratory normal reference range for thyroid function test is also included.
	Normal (Euthyroid)	Graves’ Disease	Toxic Nodules	Subacute Thyroiditis	Reference Range
TSH mIU/L	1.9 +/- 1.2	0.011 +/- 0.017	0.025 +/- 0.33	0.019 +/-0.016	0.27–4.64
T4 pmol/L	16 +/- 6.5	49 +/- 37	27 +/-12	33 +/- 22	12–22
T3 pmol/L	5 +/- 1.6	19 +/- 13	10 +/- 5	9 +/- 4	3.1–6.8

Figure 1 shows mean and range of 99mTc thyroid uptake for euthyroid and thyrotoxic patient groups. Normal mean and range of 99mTc uptake were 1.5 +/- 1.1% and 0.17–4.8%, respectively. Mean 99mTc uptake is markedly high in hyperthyroid patients and extremely low in subacute thyroiditis patients, but there is an overlap between ranges of thyrotoxic patient groups and normal individuals (euthyroid) as noted in Fig. 1. Table 3 and Figs. 2–3 show that 99mTc uptake was uncertain (overlap with normal range) in 39 hyperthyroid patients while radioiodine uptake was high in all of them. Eleven euthyroid patients underwent both Tc99m and radioiodine uptake which was normal in both radiotracers (Fig. 4).

Table 3

showing mean and range 131I thyroid uptake in hyperthyroid (Graves’ disease or toxic nodules) group and subacute thyroiditis group who have uncertain 99mTc uptake (overlap with normal range) as well as in 11 euthyroid patients.
Radiotracer	Normal (Euthyroid)		Graves’ Disease		Toxic Nodules		Subacute Thyroiditis
	no.	Uptake% Range (mean +/- SD)	no.	Uptake% Range (mean +/- SD)	no.	Uptake% Range (mean +/- SD)	no.	Uptake% Range (mean +/- SD)
131I	11	5–17 (12 +/- 4)	28	20–61 (35 +/- 10)	11	20–38 (28 +/-6)	10	0.2–5.1 (1.9 +/-1.5)
99mTc	11	0.2–4.9 (1.4 +/-1)	28	0.43–3.5 (2 +/- 0.9)	11	0.6–3.6 (1.4 +/-1)	10	0.1–0.7 (0.3 +/-0.2)

Figure 1 shows that mean 99mTc thyroid uptake was extremely low (< 1%) in subacute thyroiditis patients. However, 10 out of 17 subacute thyroiditis patients had uncertain 99mTc thyroid uptake as uptake (overlap with normal range). Accordingly, those 10 patients underwent radioiodine thyroid uptake which was low (Table 3 and Fig. 5).

Hyperthyroid patients (Graves’ disease and toxic nodules) were followed-up clinically for at least 6 months while subacute thyroiditis patients were followed-up clinically for at least 2 months (Table 4). Graves’ disease patients and toxic nodules’ patients were treated successfully by anti-thyroid medications and/or by radioiodine ablation. Most patients with subacute thyroiditis recovered within 2–3 months (Table 4).

Table 4

showing follow up duration range, type of treatment and treatment outcome in each patient group.
	Follow-up Duration (mo)	Anti-thyroid Treatment (n)	I131 Ablation (n)	Outcome		Total (n)
	Follow-up Duration (mo)	Anti-thyroid Treatment (n)	I131 Ablation (n)	Hypothyroid (n)	Recovery (n)	Total (n)
Euthyroid	-	-	-	-	-	54
Graves Disease	6–30	107	65*	65	47	112
Toxic Nodules	6–24	4	22	5	21	26
Subacute Thyroiditis	2–6	0	0	3	14	17
*Sixty patients failed anti-thyroid treatment for 1-1.5 year duration and referred for radioiodine ablation. The remainder 5 patients immediately underwent radioiodine ablation.

Sensitivity, specificity, PPV, NPV and accuracy of 99mTc thyroid uptake in thyrotoxicosis were as follow: sensitivity was 68%, specificity was 100%, PPV was 100%, NPV was 52% and accuracy was 76%.

Thyroid uptake value along with thyroid scintigraphic features provides useful information on the etiology of thyrotoxicosis. Reduced uptake value with poor visualization of thyroid gland is often associated with subacute thyroiditis whereas elevated uptake value with diffusely enlarged thyroid or focal nodules is often seen in patients with Graves’ disease or toxic nodular goiter (1, 2).

99mTc pertechnetate is becoming the radiotracer of choice in thyroid uptake evaluation owing to its low cost, ready availability, rapid single visit imaging, lower radiation burden to the patient and good image quality (1).

Although 99mTc does not undergo organification by follicular cells like iodine; thyroid uptake of 99mTc-pertechnetate is closely correlated with radioiodine uptake in thyrotoxic patients (5). Iodine-123 (123I) provides good image quality and low radiation burden to the patient. However, 123I is expensive and not readily available as well as test is requiring a return visit by the patient next day (1). Iodine-131(131I) is abandoned in Europe and North America because of its high radiation burden on patients secondary to long half-life and beta radiation (2).

In the present study, normal range of 99mTc thyroid uptake was 0.17–4.8% and normal mean was 1.5 +/- 1.1%. Our results are very close to previously published results. In 1971, Atkin reported normal mean of 1.73 +/- 0.85% and normal range of 0.5-4% (3). A normal range of 0.4–2.5% was reported in another study (6). One more study reported normal mean of 0.9% and normal range of 0.1–6.3% (1). In contrary, one study reported a narrower normal range of 0.4–1.7% (7).

Despite all advantages of 99mTc thyroid uptake, overlap between normal uptake range in euthyroid patients and uptake range of thyrotoxic patients is considered a major disadvantage. This disadvantage is even exaggerated because the normal range of 99mTc thyroid uptake is generally low and narrow as well as neck background activity is relatively high (8–9). In concordance with that; our data showed that 28% (39/138) of our hyperthyroid patients had uncertain values of 99mTc thyroid uptake (overlap with normal range). Moreover, 59% (10/17) of subacute thyroiditis patients in our study had uncertain 99mTc thyroid uptake values (overlap with lower end of normal range). It has been reported that 8 out of 26 (31%) thyrotoxic patients had normal 99mTc thyroid uptake (4). In another study, 24 out of 201 (12%) Graves’ disease patients had normal 99mTc uptake (6). In addition, it was found that 99mTc thyroid uptake in 57 Graves’ disease patients ranged from 0.97%-40.1% (10).

In order to overcome disadvantages of 99mTc thyroid uptake; we added second thyroid uptake test utilizing radioiodine for thyrotoxic patients who had uncertain 99mTc uptake values (overlap with normal range). Radioiodine uptake was high in all 28% of hyperthyroid patients with uncertain 99mTc uptake value. As well; radioiodine uptake was low in 11 subacute thyroiditis patients with uncertain 99mTc uptake value.

To confirm the results of thyroid uptake test in our patients we reviewed the medical records of our patients. All patients diagnosed with Graves’ disease or toxic nodules by 99mTc alone or by 99mTc/radioiodine were treated by anti-thyroid medications and/or radioiodine ablation. Outcome in those patients was good (recovery or hypothyroidism) reflecting that our approach succeeded in overcoming the uncertainty of 99mTc in thyrotoxicosis evaluation. Similarly, we noted good outcome in patients diagnosed to have subacute thyroiditis by this approach. Most of them recovered spontaneously and few of them became hypothyroid.

Statistically, 99mTc thyroid scan is found to be specific in thyrotoxicosis evaluation. However, uncertain values of this test degraded sensitivity and accuracy of the test which were found to be 68% and 76% respectively. Adding second radioiodine uptake test to uncertain cases managed to overcome this disadvantage. In another word, third of thyrotoxic patients are expected to have uncertain 99mTc thyroid uptake values overlapping with normal range. By combining radioiodine thyroid uptake to 99mTc uptake in this circumstance, we could reach accurate diagnosis in those patients. Two thirds of thyrotoxic patients will gain advantages of 99mTc thyroid uptake i.e single visit test, good image quality and low radiation burden (1). This approach is found very helpful in our department as radioiodine 131I is available for imaging not radioiodine 123I which is expensive and of relative short half-life. By this approach, we managed to abandon radioiodine 131I from 2 thirds of our patients and at the same time we continued to have accurate diagnosis in all patients. We believe that this approach is helpful in most developing countries where radioiodine 123I is not readily available.

We admit that third of our patients who underwent combined 99mTc/131I thyroid uptake received higher radiation dose. The dose to the thyroid from 131I is about 100 times greater than that from 123I for the same administered activity (≈ 1 rad/µCi [10 mGy/0.037 MBq] versus 1 rad/100 µCi [10 mGy/3.7 MBq]). The absorbed thyroid dose from 99mTc-pertechnetate is about 1 rad/5000 µCi (10 mGy/185 MBq) (11). The average administered dose is 5 mCi (185 MBq) 99mTc which results in 1 rad radiation absorption to thyroid. This is a negligible radiation absorbed dose as compared to that resulting from radioiodine.

This study showed that 99mTc thyroid uptake is the test of choice for evaluation of thyrotoxic patients for several reasons; the most important is being performed in single visit. Second important reason is that we managed to abandon 131I radioiodine from thyroid imaging as 123I radioiodine is not available in our country which is true for most developing countries. However, its major disadvantage is the uncertainty as third of our patients had uncertain thyroid uptake values overlapping with normal range. This uncertainty degraded test sensitivity and accuracy. We managed to overcome this uncertainty by adding second radioiodine thyroid uptake test in patients with uncertain 99mTc thyroid uptake. According to this approach, single visit 99mTc thyroid uptake was accurate and sufficient in about two thirds of our thyrotoxic patients while the remainder third of our patients with uncertain 99mTc thyroid uptake values required additional 2-day visit radioiodine thyroid uptake to reach accurate diagnosis.

TcTU

99mTc thyroid uptake

TFT

thyroid function text

TSH

stimulating hormone

99mTc

Technetium-99m

123I

Iodine-123

131I

Iodine-131

PPV

positive predicative valve

NPV

negative predicative value

RIU

radioiodine uptake

Cpm

counts per minute

- Ethics approval and consent to participate: The study was approved by Jordan University of Science and Technology institutional review board (IRB) headed by Dr Yosuf Khader ( phone # 962796802040). Consents were waived according to hospital policy.

- Consent to publish: not applicable

- Availability of data and materials: The datasets used and/or analyzed during the current study are available from the corresponding authors on reasonable request

- Competing interests: authors have no conflict of interest to declare

- Funding: this work did not receive any kind of funding

- Authors' Contributions:

Methodology introduction, reading scan and uptake and writing the paper

Patient referral and clinical diagnosis and follow up

As a radiopharmacist, she prepared doses and validated uptake values

Read scan and uptake and participated in writing discussion

Data collection and clinical follow up

***Please note that all authors have read and approved the manuscript

- Acknowledgements: not applicable

Macauley M, Shawgi M, Ali T, Curry A, Howe K, Howell E, et al. Assessment of normal reference values for thyroid uptake of technetium-99m pertechnetate in a single centre UK population. Nucl Med Commun. 2018;39:834–8.
Al-Muqbel KM, Tashtoush RM. Patterns of thyroid radioiodine uptake: Jordanian experience. J Nucl Med Technol. 2010;38:32–6.
Atkins HL. Technetium-99m pertechnetate uptake and scanning in the evaluation of thyroid function. Semin Nucl Med. 1971;1:345–55.
Sucupira MS, Camargo EE, Nickoloff EL, Alderson PO, Wagner HN Jr. The role of 99mTc pertechnetate uptake in the evaluation of thyroid function. Int J Nucl Med Biol. 1983;10:29–33.
Uchida T, Suzuki R, Kasai T, Onose H, Komiya K, Goto H, et al. Cutoff value of thyroid uptake of (99 m)Tc-pertechnetate to discriminate between Graves' disease and painless thyroiditis: a single center retrospective study. Endocr J. 2016;63:143–9.
Ikekubo K, Hino M, Ito H, Koh T, Ishihara T, Kurahachi H, et al. Thyrotoxic Graves’ disease with normal thyroidal technetium-99m pertechnetate uptake. Ann Nucl Med. 1990;4:43–8.
Ramos CD, Zantut Wittmann DE, Etchebehere EC, Tambascia MA, Silva CA, Camargo EE. Thyroid uptake and scintigraphy using 99mTc pertechnetate: standardization in normal individuals. Sao Paulo Med J. 2002;120:45–8.
Maisey MN, Natarajan TK, Hurley PJ, Wagner HN Jr. Validation of a rapid computerized method of measuring 99mTc pertechnetate uptake for routine assessment of thyroid structure and function. J Clin Endocrinol Metab. 1973;36:317–22.
Schneider PB. Simple, rapid thyroid function testing with 99mTc pertechnetate thyroid uptake ratio and neck/thigh ratio. AJR Am J Roentgenol. 1979;132:249–53.
Kidokoro-Kunii Y, Emoto N, Cho K, Oikawa S. Analysis of the factors associated with Tc-99m pertechnetate uptake in thyrotoxicosis and graves' disease. J Nippon Med Sch. 2006;73:10–7.
Fred A, Mettler, Jr, Milton J Guiberteau. Essentials of Nuclear Medicine Imaging. 6th ed. Saunders; 2012.

response.docx

Download PDF

Version 1

posted

You are reading this latest preprint version

Is 99mTechnetium Pertechnetate Thyroid Uptake accurate in Thyrotoxicosis Evaluation?

Status:

Version 1

Abstract

Figures

Background

Methods

Statistics:

Technique:

99mTc Scintiscan:

99mTc Thyroid uptake measurement:

Measurement of 24-hour radioiodine Thyroid uptake:

Results

Discussion

Conclusion

Abbreviations

Declarations

References

Supplementary Files

Status:

Version 1